Could group video calls replace One-on-One prostate cancer checkups?
NCT ID NCT05416996
First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times
Summary
This study compares group telemedicine appointments to individual video visits for men with prostate cancer who are on active surveillance. Researchers want to see if the group format is practical and acceptable, and how it affects patient satisfaction and quality of life. The study involves 88 participants from a single cancer center.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- telemedicine shared medical appointments
- What this could lead to
- If successful, this could offer a convenient, satisfying way for men with prostate cancer on active surveillance to have follow-up care without traveling to the doctor alone.
- What could go wrong
- This is a small feasibility study (88 participants) at a single center, so results may not apply broadly. It does not test cancer outcomes, only satisfaction and adherence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
88 people
The number who actually took part.
- Started
-
Jun 2022
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients will be recruited through two routes: 1) by physician invitation during routine Active Surveillance (AS) office visits or 2) by the physician's assistant or research team calling.
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A scheduled appointment for a subsequent Active Surveillance (AS) follow-up visit for management of localized prostate cancer * Biopsy Gleason score 3+3=6 (Grade Group 1) or biopsy Gleason score 3+4=7 (Grade Group 2) * Clinical T stage ≤T2B * Access to a device with Zoom * Ability to speak and understand English Exclusion Criteria: * Plan to undergo a prostate biopsy at this follow-up visit
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Localized prostate cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive missile aims at prostate cancer that spread
- New PET tracer targets ACP3 to spot prostate cancer
- Can a One-Week radiation course match four weeks for prostate cancer?
- Can a new PET tracer spot hidden prostate cancer spread?
- Can a gel cushion shield the rectum during prostate radiation?
- A scanner in the operating room could show surgeons exactly where prostate cancer remains